These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 2140408)

  • 1. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.
    Kung HF; Alavi A; Chang W; Kung MP; Keyes JW; Velchik MG; Billings J; Pan S; Noto R; Rausch
    J Nucl Med; 1990 May; 31(5):573-9. PubMed ID: 2140408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.
    Kung HF; Pan S; Kung MP; Billings J; Kasliwal R; Reilley J; Alavi A
    J Nucl Med; 1989 Jan; 30(1):88-92. PubMed ID: 2783457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD; Abrams DN; Greenberg CR; Hobson D
    J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases.
    Buck A; Westera G; Sutter M; Albani C; Kung HF; vonSchulthess GK
    J Nucl Med; 1995 Jul; 36(7):1196-200. PubMed ID: 7790944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
    Cordes M; Henkes H; Laudahn D; Bräu H; Kramp W; Girke W; Hierholzer J; Eichstädt H; Felix R
    Eur J Radiol; 1991; 12(3):182-6. PubMed ID: 1830273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of dopamine D2 receptors. Preparation of 125I-IBZM and its biodistribution and kinetic properties].
    Matsumura K; Toyama H; Nakashima H; Ichise M; Kurami M; Nakagawa T; Maeda H; Takeuchi A; Koga S
    Kaku Igaku; 1994 May; 31(5):513-9. PubMed ID: 8028224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intravenous and intraperitoneal [123I]IBZM injection for dopamine D2 receptor imaging in mice.
    Meyer PT; Salber D; Schiefer J; Cremer M; Schaefer WM; Kosinski CM; Langen KJ
    Nucl Med Biol; 2008 Jul; 35(5):543-8. PubMed ID: 18589298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease.
    Knable MB; Jones DW; Coppola R; Hyde TM; Lee KS; Gorey J; Weinberger DR
    J Nucl Med; 1995 Jul; 36(7):1216-25. PubMed ID: 7790947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
    Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.
    Kung HF; Guo YZ; Billings J; Xu X; Mach RH; Blau M; Ackerhalt RE
    Int J Rad Appl Instrum B; 1988; 15(2):195-201. PubMed ID: 2966782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.
    Innis RB; Malison RT; al-Tikriti M; Hoffer PB; Sybirska EH; Seibyl JP; Zoghbi SS; Baldwin RM; Laruelle M; Smith EO
    Synapse; 1992 Mar; 10(3):177-84. PubMed ID: 1532675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients.
    Vallabhajosula S; Hirschowitz J; Machac J
    J Nucl Med; 1997 Feb; 38(2):203-7. PubMed ID: 9025736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand.
    Votaw JR; Ansari MS; Mason NS; Schmidt D; de Paulis T; Holburn G; Clanton JA; Votaw DB; Manning RG; Kessler RM
    J Nucl Med; 1995 Jul; 36(7):1316-21. PubMed ID: 7790962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
    Brücke T; Podreka I; Angelberger P; Wenger S; Topitz A; Küfferle B; Müller C; Deecke L
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):220-8. PubMed ID: 1671782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
    de Herder WW; Reijs AE; de Swart J; Kaandorp Y; Lamberts SW; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.